NCT00001789View on ClinicalTrials.gov

BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis

PHASE2CompletedINTERVENTIONAL
Enrollment

20

Participants

Timeline

Start Date

June 30, 1999

Study Completion Date

May 31, 2000

Conditions
Glomerulonephritis, MembranoproliferativeLupus Nephritis
Interventions
DRUG

BG9588

Trial Locations (1)

20892

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS), Bethesda

All Listed Sponsors
lead

National Institute of Arthritis and Musculoskeletal and Skin Diseases (NIAMS)

NIH

NCT00001789 - BG9588 (Anti-CD40L Antibody) to Treat Lupus Nephritis | Biotech Hunter | Biotech Hunter